This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Evaxion Biotech A/S


Evaxion-Biotech A/S (NASDAQ:EVAX) is a clinical-stage biotech company developing AI-powered immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. 

Our cancer portfolio is focussed on personalised neoantigen-targeting immunotherapies. We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers. 

EVX-01 has now entered phase 2b testing in metastatic melanoma following promising data from the phase 1/2a clinical trial with clear signs of clinical efficacy. We are completing a phase 1/2a trial with EVX-02 in adjuvant melanoma. Our third oncology program, EVX-03,  is in preparation for clinical development within NSCLC.

Our infectious disease portfolio comprises EVX-B1 and EVX-B2.

EVX-B1 is a multi-component subunit vaccine for the prevention of S. aureus infections and is at IND-enabling stage. EVX-B2 is a vaccine against N. gonorrhoea  in preclinical development. 

We will soon be announcing EVX-V1, our first viral vaccine project.

All our pipeline projects are derived from our proprietary AI platforms: (i) PIONEER™, our immuno-oncology platform, (ii) EDEN™, our bacterial disease platform, and (iii) RAVEN™, our viral disease platform.